--- title: An Evaluation of Remote Care (Questionnaire+Hybrid) in Patients Who Are Post-lung Transplant nct_id: NCT05916495 overall_status: COMPLETED phase: NA sponsor: University of Manchester study_type: INTERVENTIONAL primary_condition: Lung Transplant; Complications countries: United Kingdom canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05916495.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05916495" ct_last_update_post_date: 2026-04-13 last_seen_at: "2026-05-12T06:27:28.985Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # An Evaluation of Remote Care (Questionnaire+Hybrid) in Patients Who Are Post-lung Transplant **NCT ID:** [NCT05916495](https://clinicaltrials.gov/study/NCT05916495) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 76 - **Lead Sponsor:** University of Manchester - **Collaborators:** patientMpower Ltd., Manchester University NHS Foundation Trust, University College, London, New Start, The Wythenshawe Hospital Transplant Fund Centre - **Conditions:** Lung Transplant; Complications - **Start Date:** 2023-09-29 - **Completion Date:** 2025-02-27 - **CT.gov Last Update:** 2026-04-13 ## Brief Summary Lung transplantation is used to treat patients with lung damage when there is no other treatment option. Patients require close monitoring following their transplant, with hospital check-ups every 3-4 months usually lasting all day. Although check-ups often result in no change to patient management they are essential as patients have better outcomes if complications are detected quickly. The aim is to explore whether remote monitoring via an app (patientMpower) ± questionnaire (specifically designed to assess post-transplant patients' health), linked to a device to measure lung function, could replace some check-ups for lung transplant patients. Patients will be randomised to receive either normal care or remote monitoring (i.e. their symptoms will be evaluated using home spirometry combined with a questionnaire). 100 lung transplant recipients will be enrolled with 50 patients being assigned to either group. Health outcomes and costs of care between the two groups will be compared ## Detailed Description 100 lung transplant patients are expected to be recruited. Consent will be taken by the research team. Following admission they will be randomised to the interventional or control arms. The control arm will consist of follow-up according to unit policy, in the majority of cases this will be every 3 months. The only change is that when they come to follow up the patients will be asked to fill in the same interventional questionnaire (designed to assess post-transplant lung health) that the interventional arm are completing. However, they will be seen regardless of what this questionnaire reports. This will act as validation for the questionnaire. The interventional arm will replace the 3 monthly visits with a questionnaire which the patient will be asked to complete and then this will be returned to the unit. The patient can fill this in via the app, or on paper and return the questionnaire via email or post. The duty clinician will then review the questionnaire and combine this with the home spirometry data which the patient is already completing to see if the patient needs to be seen. In the majority of cases, its expected that the patient will not need to be seen as the clinic visits in lung transplant are mainly monitored and the vast majority of the patients are seen every 3-4 months. Regardless of the outcome, the participant will receive a phone call from the transplant nurse within 48 hours of the appointment to discuss the results of the blood test and confirm that they are okay. In addition to the questionnaire to assess lung health, all participants will be asked to complete other respiratory/sleep questionnaires such as Saint George's Respiratory (SGRQ), Morningness-eveningness (MEQ-SA) and the Pittsburgh Sleep Quality Index (PSQI). This will investigate whether more complex questionnaires are needed to see if patients require clinical follow-up. Study duration is predicted to be 6 months per participant. During the whole study, volunteers will be asked to wear an activity tracker such as Fitbit. Using the device's application programming interface (API) investigators will be able to remotely access data concerning heart rate, accelerometry and sleep duration, including stages of sleep. This will be accessed as required anticipated to be once per week, followed by phone calls to patients should the data be missing. In addition, their clinical record will also be accessed to obtain clinical data for instance if a sleep study has been performed. Patients will be asked to perform daily home spirometry using a Bluetooth enabled spirometer. It is currently being used in the Manchester lung transplant program. If patients have not submitted a reading for one week then they will be contacted by the study team to offer assistance. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 90 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Looked after by a clinical care team at Manchester University NHS Foundation Trust * Given consent * Have received a lung transplant Exclusion Criteria: * Consent not given * Not able to operate the remote monitoring platform ``` ## Arms - **Hybrid care arm** (EXPERIMENTAL) — Remote review of information collected electronically will be combined with in person visits at a hospital - **Standard of care arm** (ACTIVE_COMPARATOR) — Patients will be seen in person at a hospital clinic. ## Interventions - **Hybrid care arm** (OTHER) — Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry). - **Standard of care arm** (OTHER) — Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry). ## Primary Outcomes - **Number of clinic visits per patient** _(time frame: 6 months)_ — The number of clinic follow up visits in the observation period ## Secondary Outcomes - **Number of unplanned clinic visits per patient** _(time frame: 6 months)_ - **"Measuring the Utilization Rate of Remote Monitoring for Patient Engagement" "Measuring the Utilization Rate of Remote Monitoring for Patient Engagement" Number of patient interactions with the remote monitoring platform** _(time frame: 6 months)_ - **Hospitalisation due to deterioration of allograft function** _(time frame: 6 Months)_ - **Duration of hospitalisations due to deterioration of allograft function** _(time frame: 6 Months)_ - **Number of planned clinic visits per patient** _(time frame: 6 Months)_ - **Number of patients where symptoms were recorded accurately on the questionnaire** _(time frame: 6 months)_ ## Locations (1) - Manchester University NHS Foundation Trust, Manchester, United Kingdom ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.manchester university nhs foundation trust|manchester||united kingdom` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT05916495.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT05916495* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*